Efficacy and Safety of Bepridil for Patients with Persistent Atrial Fibrillation after Failed Electrical Cardioversion

Journal of Arrhythmia

Volumn 27, Issue 2, 2011, Pages 131-136

  Egami, Yasuyuki ^a   Nishino, Masami ^a   Taniike, Masayuki ^a   Makino, Nobuhiko ^a   Kato, Hiroyasu ^a   Shutta, Ryu ^a   Tanouchi, Jun ^a   Yamada, Yoshio ^a  

^a OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

Antiarrhythmic agent; Atrial fibrillation; Bepridil; Cardioversion

Indexed keywords

EID: 84870394414     PISSN: 18804276     EISSN: 18832148     Source Type: Journal    
DOI: 10.4020/jhrs.27.131     Document Type: Article

References (24)

1. Kannel WB, Abbott RD, Savage DD, et al: Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018-1022
2. Krahn AD, Manfreda J, Tate RB, et al: The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 476-484
3. Wellens HJ: Atrial fibrillation-the last big hurdle in treating supraventricular tachycardia. N Engl J Med 1994; 331: 944-945
4. Hohnloser SH, Kuck KH, Lilienthal J: Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789-1794
5. Wyse DG, Waldo AL, DiMarco JP, et al: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833
6. Carlsson J, Miketic S, Windeler J, et al: Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41: 1690-1696
7. Dorian P, Jung W, Newman D, et al: The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 2000; 36: 1303-1309
8. Ogawa S, Yamashita T, Yamazaki T, et al: Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 2009; 73: 242-248
9. Harder DR, Sperelakis N: Bepridil blockade of Ca2+- dependent action potentials in vascular smooth muscle of dog coronary artery. J Cardiovasc Pharmacol 1981; 3: 906-914
10. DiBianco R, Alpert J, Katz RJ, et al: Bepridil for chronic stable angina pectoris: results of a prospective multicenter, placebo-controlled, dose-ranging study in 77 patients. Am J Cardiol 1984; 53: 35-41
11. Anno T, Furuta T, Itho M, et al: Effects of bepridil on the electrophysiological properties of guinea-pig ventricular muscles. Br J Pharmacol 1984; 81: 589-597
12. Wang JC, Kiyosue T, Kiriyama K, et al: Bepridil differentially inhibits two delayed rectifier K(+) currents, I(Kr) and I(Ks), in guinea-pig ventricular myocytes. Br J Pharmacol 1999; 128: 1733-1738
13. Fujiki A, Tsuneda T, Sugao M, et al: Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol 2003; 92: 472-475
14. Nakazato Y, Yasuda M, Sasaki A, et al: Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J 2005; 69: 44-48
15. Perelman MS, McKenna WJ, Rowland E, et al: A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation. Br Heart J 1987; 58: 339-344
16. Hart RG, Sherman DG, Easton JD, Cairns JA: Prevention of stroke in patients withnonvalvular atrial fibrillation. Neurology 1998; 51: 674-681
17. Hylek EM, Skates SJ, Sheehan MA, et al: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-546
18. Silverman DI, Manning WJ: Role of echocardiography in patients undergoing elective cardioversion of atrial fibrillation. Circulation 1998; 98: 479-486
19. Yoshida T, Niwano S, Inuo K, et al: Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. Pacing Clin Electrophysiol 2003; 26: 314-317
20. Kobayashi S, Reien Y, Ogura T, et al: Inhibitory effect of bepridil on hKv1.5 channel current: comparison with amiodarone and E-4031. Eur J Pharmacol 2001; 430: 149-157
21. Yoshida T, Niwano S, Inuo K, et al: Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings. Circ J 2003; 67: 11-15
22. Roy D, Talajic M, Dorian P, et al: Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342: 913-920
23. Yasuda M, Nakazato Y, Sasaki A, et al: Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. Circ J 2006; 70: 662-666
24. Yamashita T, Ogawa S, Sato T, et al: Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled, double-blind study (J-BAF Study). Circ J 2009; 73: 1020-1027